IEEE VLSI Symposium

2012, 151. 13. Jung J, Cho W: Tunnel barrier engineering for non-volatile memory. J Semicond Tech Sci 2008, 8:No. 1, 33. 14. Woo J, Jung S, Siddik M, Cha E, Sadaf S, Hwang H: Effect of interfacial oxide layer on the switching uniformity of Ge2Sb2Te5-based resistive change memory devices. AIP Applied Physics Letters 2011, 99:162109. 10.1063/1.3656247CrossRef 15. Chen A: Switching control of resistive switching www.selleckchem.com/products/4egi-1.html devices. AIP Appl Phys Lett 2010, 97:263505. 10.1063/1.3532969CrossRef 16. Sriraman V, Chen Z, Li X, Wang X, Singh N, Lo G: HfO 2 based resistive switching non-volatile memory (RRAM) and its potential for embedded applications. International Conference Solid-State Integration Circuit 2012, 32. 17. Chen B, Lu Y, Gao B, Fu Y, Zhang F, Huang P, Chen Y, Liu L, Kang J, Wang Y, Fang Z, Yu H, Li X, Wang X, Singh N, Lo G, Kwong D: Physical mechanisms of endurance degradation in TMO-RRAM. PI3K Inhibitor Library solubility dmso IEEE International Electron Devices Meeting 2011, 283. Competing interests The Selleckchem Daporinad Authors declare that they have no competing interests. Authors’ contributions

SL had studied and analyzed behaviors of resistive random access memory (ReRAM) for high selectivity and switching uniformity. He observed that the TiOx tunnel barrier plays an important role in selectivity and switching uniformity. Firstly, JW observed the non-linear behavior of Flucloronide the ReRAM in our group. DL participated in the switching

uniformity analysis. EC participated in the study of the filament growth. Prof. HH comprehensively understands this work as an advisor. All authors have read and approved the final manuscript.”
“Background Nanotechnology is a rapidly advancing and key field of drug delivery. A great variety of nanoparticle (NP)-based therapeutic products have entered clinical development or been approved for clinical use [1]. As an excellent biocompatible and biodegradable nanomaterial with low toxicity and immunogenicity, chitosan (CS)-based nanocarriers presented great advantages for drug, protein, and gene delivery in therapeutics [2–5]. However, most CS-based nanocarriers were easily sequestered by macrophages in the mononuclear phagocyte system (MPS) after intravenous administration. To avoid the rapid clearance of the CS-NPs during circulation, PEGylation can be used to improve the physiological stability, reduce the opsonization, and increase the possibility reaching the tumor by the enhanced permeation and retention (EPR) effect (40 to 400 nm) [6–8]. Despite these advantages of the passive targeting, the main obstacle encountered with the clinical use of the PEGylated CS-NPs is how to facilitate their internalization in the target cells while reducing the unintended side effects. One strategy is the further functionalization of the PEGylated CS-NPs with active targeting agents.